March of Dimes and Anthem Foundation, the philanthropic arm of Anthem, Inc., today announced a $1.1 million grant with their latest plans to tackle America's maternal and infant health crisis

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

CELLECTRA® 3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response

Each NCS Group Unlimited Carrier Fleet Vehicle brings a total of $180K+ worth of supplies and aid, and a total of six trucks are arriving in Texas